These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24935593)

  • 21. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
    Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
    Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.
    Xie N; Wang Y; Wang Q; Li FR; Guo B
    Bull Cancer; 2012 May; 99(5):E55-63. PubMed ID: 22522606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.
    Reiter Z; Ozes ON; Blatt LM; Taylor MW
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 1):103-11. PubMed ID: 1370257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
    Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
    Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
    Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z
    Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
    Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
    BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
    Tietje A; Li J; Yu X; Wei Y
    Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.
    Le Maux Chansac B; Moretta A; Vergnon I; Opolon P; Lécluse Y; Grunenwald D; Kubin M; Soria JC; Chouaib S; Mami-Chouaib F
    J Immunol; 2005 Nov; 175(9):5790-8. PubMed ID: 16237071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
    Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
    Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes.
    Ashiru O; Boutet P; Fernández-Messina L; Agüera-González S; Skepper JN; Valés-Gómez M; Reyburn HT
    Cancer Res; 2010 Jan; 70(2):481-9. PubMed ID: 20068167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
    Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
    Jin GH; Hirano T; Murakami M
    Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
    Shi P; Yin T; Zhou F; Cui P; Gou S; Wang C
    BMC Cancer; 2014 May; 14():370. PubMed ID: 24885711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
    Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.